Printer Friendly

Aegis Therapeutics Invited to Present at the Health Care Ventures 2005 Conference.

SAN DIEGO -- Aegis Therapeutics LLC will be presenting at the Health Care Ventures 2005 Conference, sponsored by Dow Jones VentureWire. Dr. Edward T. Maggio, Ph.D., President and Chief Executive Officer, will provide a corporate overview, including a review of the Company's patented Intravail(TM) technology for intranasal and transmucosal delivery of peptide, protein, and non-protein macromolecular therapeutics, on Wednesday, Sept. 28 at 9:45 AM at the Sofitel San Francisco Bay, Redwood City, CA.

The conference will include CEOs from 60 companies in the most competitive sectors -- including diabetes, obesity, oncology, neurology, personalized medicine, orthopedics, and eye disorders. Additional information on the conference may be found on the internet at the conference website:

About Aegis Therapeutics

Aegis Therapeutics LLC is a specialty pharmaceutical company commercializing its patented Intravail(TM) drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis' Intravail(TM) absorption enhancement agents are mild and non-irritating to mucosal membranes. They provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Intravail(TM) also provides for rapid drug absorption and onset of action, controlled transient permeation of the nasal mucosal barrier, avoidance of gastric hydrolysis and "first pass effect" elimination by the liver, greater patient convenience and compliance, elimination of needle-stick injuries and associated transmission of blood borne pathogens, compatibility with current nasal delivery devices, and ease of formulation, scale-up, and production. For more information about Aegis, please visit the Aegis website at:
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 18, 2005
Previous Article:Kum & Go Convenience Stores Moves to Reduce Out-Of-Stocks Using Retalix DemandAnalytix.
Next Article:Research and Markets: Thoroughly Investigative Report on The Austrian Office Products Market 2004-9 Now.

Related Articles
Aegis Therapeutics to Present at the March 2005 Health Care Ventures Conference Sponsored by Dow Jones VentureWire and Venture Capital Analyst.
Aegis Therapeutics Invited to Participate in 2006 Gordon Research Conference on Peptides.
Critical Therapeutics to Announce Second Quarter 2005 Financial Results on August 4, 2005.
Aegis Therapeutics Invited to Present Intravail(TM) Drug Delivery Technology and Participate in Panel Session at SRI's ``Peptides and Therapeutic...
Aegis Therapeutics to Present Intravail(TM) Drug Delivery Technology at CBI's 'Protein Drugs' Conference.
Aegis Therapeutics to Present at the ``TIDES'' and ``Drug Delivery 2006'' Conferences in May 2006.
C21 BioVentures Examines Trends and Topical Issues Shaping the Development of the Global Bioscience Community.
C21 BioVentures Presents an Array of Biotech Investment Opportunities.
C21 BioVentures Grows Lifescience Companies Through Partnering, Networking and Financing.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters